Using MCF7 breast cancer cells, we tested the anticancer activity of metabolites from 130 strains of myxobacteria newly isolated in South Korea. Of these, three strains whose metabolites had high anticancer activity and low cell toxicity were selected and identified by their fruiting body morphology, cell morphology, and 16S rRNA sequence. Strains KYC4030 and KYC4048 were determined to be Myxococcus fulvus, whereas strain KYC4081 was identified as Corallococcus coralloides. We found that metabolites of M. fulvus KYC4048 demonstrated no toxicity in normal cells but specifically induced cancer cell death by suppressing the expression of WNT2B. This discovery highlights the value of assessing the metabolic and biomedical potential of myxobacteria, even those that are already known but were isolated from new areas, and the possible use of metabolites from M. fulvus KYC4048 in cancer treatment.
CITATION STYLE
Lee, C., Park, S., Ayush, I., Cho, K., Kim, S. S., Kang, I., … Yoon, K. S. (2018). Effects of myxococcus fulvus KYC4048 metabolites on breast cancer cell death. Journal of Microbiology and Biotechnology, 28(5), 765–775. https://doi.org/10.4014/jmb.1711.11003
Mendeley helps you to discover research relevant for your work.